Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo targets tough lung cancer in phase 2 trial

NCT ID NCT06295432

Recruiting now Disease control Sponsor: Dizal Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jan 09, 2026 · Last updated May 15, 2026 · Updated 17 times

Summary

This study tests two experimental drugs, DZD9008 and AZD4205, taken together for advanced non-small cell lung cancer with EGFR mutations that has worsened after standard treatments. About 90 adults will participate to see if the combination is safe and shrinks tumors. The goal is to control the disease, not cure it.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Guangdong Provincial People'S Hospital

    RECRUITING

    Guangzhou, Guangdong, 510000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Henan Cancer Hospital

    RECRUITING

    Zhengzhou, China

  • The First Affiliated Hospital of Xi'an Jiaotong University

    COMPLETED

    Xi'an, China

  • Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology

    COMPLETED

    Wuhan, China

Conditions

Explore the condition pages connected to this study.

NON SMALL CELL LUNG CANCER